Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Price, Consensus and EPS Surprise
PBYI 2.54 +0.10(4.10%)
Will PBYI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PBYI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PBYI
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
Zacks.com featured highlights Abercrombie & Fitch, Puma Biotechnology, Spotify and Oddity
PBYI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
Bet on These 4 Top-Performing Liquid Stocks for Solid Gains
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Other News for PBYI
Puma Biotech confirms court ruling on patent dispute with AstraZeneca
Puma Biotech confirms court ruling on patent invalidity, disagrees with verdict
Puma Biotech drops after patents ruled invalid in fight with AstraZeneca over Tagrisso
Puma Biotech drops after patents ruled invalid in fight with AstraZeneca over Tagrisso
Puma Biotechnology quickly drops after patents for Tagrisso ruled invalid